The Procter & Gamble Company
PG · NYSE
Analyst ratings
buy · 12 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 16, 2026 | JP Morgan | Maintains | Overweight | $162.00 |
| July 10, 2026 | B of A Securities | Maintains | Buy | $166.00 |
| April 27, 2026 | UBS | Maintains | Buy | $172.00 |
| April 27, 2026 | TD Cowen | Maintains | Hold | $150.00 |
| April 27, 2026 | Wells Fargo | Maintains | Overweight | $164.00 |
| April 27, 2026 | Evercore ISI Group | Maintains | In-Line | $162.00 |
| April 17, 2026 | JP Morgan | Maintains | Overweight | $162.00 |
| April 14, 2026 | Barclays | Maintains | Equal-Weight | $146.00 |
| April 10, 2026 | B of A Securities | Maintains | Buy | $167.00 |
| April 8, 2026 | Wells Fargo | Maintains | Overweight | $158.00 |
| April 8, 2026 | Piper Sandler | Maintains | Neutral | $142.00 |
| April 7, 2026 | UBS | Maintains | Buy | $166.00 |
| March 30, 2026 | Deutsche Bank | Maintains | Hold | $162.00 |
| January 27, 2026 | TD Cowen | Downgrades | Hold | $156.00 |
| January 23, 2026 | UBS | Maintains | Buy | $170.00 |
| January 23, 2026 | Wells Fargo | Maintains | Overweight | $165.00 |
| January 23, 2026 | JP Morgan | Upgrades | Overweight | $165.00 |
| January 14, 2026 | UBS | Maintains | Buy | $161.00 |
| January 8, 2026 | TD Cowen | Maintains | Buy | $150.00 |
| January 5, 2026 | Wells Fargo | Maintains | Overweight | $158.00 |
| December 18, 2025 | JP Morgan | Maintains | Neutral | $157.00 |
| December 17, 2025 | Jefferies | Upgrades | Buy | $179.00 |
| October 29, 2025 | Freedom Broker | Maintains | Hold | $169.00 |
| October 27, 2025 | JP Morgan | Maintains | Neutral | $165.00 |
| October 20, 2025 | Raymond James | Maintains | Outperform | $175.00 |
| October 10, 2025 | JP Morgan | Maintains | Neutral | $163.00 |
| October 8, 2025 | B of A Securities | Maintains | Buy | $174.00 |
| October 8, 2025 | UBS | Maintains | Buy | $176.00 |
| October 1, 2025 | Barclays | Maintains | Equal-Weight | $153.00 |
| September 25, 2025 | Wells Fargo | Maintains | Overweight | $170.00 |
Valuation premium vs. growth prospects justification
P&G's premium valuation is justified by its 69 consecutive years of dividend growth, consistent earnings beats, and strategic initiatives like Supply Chain 3.0. Analysts at JPMorgan maintain an Overweight rating, and the consensus price target of ~$163 reflects confidence in operational efficiency and sustained cash flow generation supporting the current multiples.
P&G trades at a Forward P/E of 20.88, a notable premium to the industry average of 18.73, with a PEG ratio of 6.27 — a red flag for growth-adjusted value. Zacks assigns a #4 (Sell) rank, and the EPS consensus estimate has fallen 0.26% over the past month, suggesting the premium valuation is difficult to sustain given modest earnings growth.
Revenue growth trajectory and consumer demand resilience
Analysts project P&G's annual revenue to reach $87.15 billion, a 3.4% increase year-over-year, with net sales for the upcoming quarter expected to grow 2.58%. Firms like Jefferies and BMO Capital have raised their price targets, reflecting confidence in P&G's ability to sustain volume growth despite a challenging consumer environment.
Consumer demand softness and competitive pressures in the staples sector pose real risks to revenue momentum. UBS flagged that consumer staple companies likely faced another 'tricky' quarter, and Goldman Sachs cut its price target to $152, signaling skepticism about near-term top-line acceleration amid economic headwinds.
Technical signals and short-term stock price direction
A buy signal was triggered from a pivot bottom in mid-July 2025, with the stock rising 3.68% since. Short-term moving averages confirm upward momentum, and Barchart's 20-day moving average registers a Buy signal. The stock's low volatility and strong liquidity make it a low-risk accumulation candidate for near-term recovery.
Despite short-term buy signals, the long-term moving average sits above the short-term average, generating an overarching sell signal. The 3-month MACD also confirms a sell, and the stock is projected to fall approximately 3.68% over the next three months. Technical weakness contrasts with fundamental strength, creating near-term uncertainty.